Semaglutide Reduces Body Fat in Obese Diabetes Patients Regardless of Formulation

Both oral and subcutaneous semaglutide significantly reduced fat mass and improved metabolic parameters in obese type 2 diabetes patients over 24 weeks.

Rodríguez Jiménez, Beatriz et al.·Frontiers in endocrinology·2024·Moderate Evidencecohort
RPEP-09164CohortModerate Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
cohort
Evidence
Moderate Evidence
Sample
Adults with type 2 diabetes and obesity (BMI ≥ 30 kg/m²)
Participants
Adults with type 2 diabetes and obesity (BMI ≥ 30 kg/m²)

What This Study Found

Both oral and subcutaneous semaglutide significantly reduced fat mass and improved metabolic parameters in adults with obesity and type 2 diabetes over 24 weeks.

Key Numbers

24-week study in adults with type 2 diabetes and BMI ≥ 30 kg/m². Both daily oral and weekly subcutaneous semaglutide were used. Body composition measured by bioelectrical impedance analysis.

How They Did This

24-week quasi-experimental retrospective study using bioelectrical impedance analysis to measure body composition changes.

Why This Research Matters

Knowing that semaglutide reduces fat specifically — not just total weight — is important because fat loss drives the metabolic health benefits, while muscle preservation maintains function and metabolism.

The Bigger Picture

Knowing semaglutide reduces fat specifically (not just weight) and that this occurs with both oral and injectable forms helps patients and doctors choose the most appropriate formulation without worrying about differential body composition effects.

What This Study Doesn't Tell Us

Retrospective study design without randomization to oral versus subcutaneous groups. Bioelectrical impedance is less precise than DEXA scanning for body composition.

Questions This Raises

  • ?Does one formulation produce better fat loss than the other?
  • ?Would longer treatment duration show continued fat loss or a plateau?

Trust & Context

Key Stat:
Both formulations effective Daily oral and weekly subcutaneous semaglutide both significantly reduced fat mass, not just total weight
Evidence Grade:
Rated moderate: quasi-experimental retrospective study with body composition data, but non-randomized comparison between oral and subcutaneous groups.
Study Age:
Published in 2024. Adds body composition data to the growing evidence base for semaglutide in both formulations.
Original Title:
Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus.
Published In:
Frontiers in endocrinology, 15, 1386542 (2024)
Database ID:
RPEP-09164

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Does semaglutide reduce fat or muscle?

This study confirmed semaglutide primarily reduces fat mass, not just total weight, using body composition analysis.

Does the oral pill work as well as the injection?

Both forms produced significant fat mass reduction and metabolic improvement over 24 weeks.

Read More on RethinkPeptides

Cite This Study

RPEP-09164·https://rethinkpeptides.com/research/RPEP-09164

APA

Rodríguez Jiménez, Beatriz; Rodríguez de Vera Gómez, Pablo; Belmonte Lomas, Samuel; Mesa Díaz, Ángel Manuel; Caballero Mateos, Irene; Galán, Irene; Morales Portillo, Cristóbal; Martínez-Brocca, María Asunción. (2024). Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus.. Frontiers in endocrinology, 15, 1386542. https://doi.org/10.3389/fendo.2024.1386542

MLA

Rodríguez Jiménez, Beatriz, et al. "Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus.." Frontiers in endocrinology, 2024. https://doi.org/10.3389/fendo.2024.1386542

RethinkPeptides

RethinkPeptides Research Database. "Transforming body composition with semaglutide in adults wit..." RPEP-09164. Retrieved from https://rethinkpeptides.com/research/rodriguez-2024-transforming-body-composition-with

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.